Efficacy and Safety of Budigalimab ± Trosunilimab in People with HIV for Durable Control of HIV without Antiretroviral Therapy: A Global, Randomized, Placebo-Controlled Phase 2 Study - Abstract
People with HIV (PWH) require lifelong antiretroviral therapy (ART), including long-acting injectables (LAI), to maintain viral suppression and reduce disease progression [1,2]. Lifelong adherence to ART, however, is often difficult owing to pill fatigue, potential long-term toxicities, and the psychosocial impact of HIV-related stigma [3–5].